Product Information

BREO ELLIPTA 200-25 MCG INHALR is a brand product labeled by GlaxoSmithKline LLC, priced at $6.5048 per EA under NDC 00173088210. Its NADAC has been published 558 times since Oct 21, 2015.

BREO ELLIPTA 200-25 MCG INHALR

fluticasone furoate and vilanterol trifenatate
$6.5048per EA

Strength

200; 25 ug/1; ug/1

NDC

00173088210

Classification

Brand

Dosage Form

POWDER

Route

RESPIRATORY (INHALATION)

Last Updated

6/17/2026

Approval Type

New Drug (NDA)

FDA Application

NDA204275

On Market Since

4/30/2015

Pharmacological Classes

Adrenergic beta2-Agonists
Corticosteroid Hormone Receptor Agonists
Corticosteroid
beta2-Adrenergic Agonist

Price Statistics

The NADAC for BREO ELLIPTA 200-25 MCG INHALR has been published 558 times since Oct 21, 2015, and over the history we have for it it has risen 44.3%. The table below summarizes its recorded NADAC range and movement.

Current price$6.5048 per EA
All-time high$6.5159 (Aug 14, 2024)
All-time low$4.5064 (Oct 21, 2015)
52-week high$6.5072
52-week low$6.5037
Median price$5.9560
Average price$5.8288
Largest weekly change+8.0% (Jan 11, 2017)
Weeks tracked558
Tracking sinceOct 21, 2015

Price History

1W

0.0%

1M

+0.0%

3M

+0.0%

6M

-0.0%

1Y

-0.0%

3Y

+2.9%

5Y

+9.2%

All

+44.3%

Generic Alternatives

The matcher finds 1 NADAC-published product sharing this drug's active ingredient, strength, and dosage form across 1 manufacturer (up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 18% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Lowest-Cost Alternatives

Save up to 18%

1 alternative • Same active ingredient

Frequently asked questions

What is the NADAC price of BREO ELLIPTA 200-25 MCG INHALR?

The current National Average Drug Acquisition Cost (NADAC) for BREO ELLIPTA 200-25 MCG INHALR, manufactured by GlaxoSmithKline LLC, is $6.5048 per EA (NDC 00173088210), effective Jun 24, 2026.

How has the price of BREO ELLIPTA 200-25 MCG INHALR changed over time?

Over the history we have for it, the NADAC for BREO ELLIPTA 200-25 MCG INHALR has risen 44.3%. It has been tracked across 558 weekly CMS publications since Oct 21, 2015.

What are the highest and lowest recorded NADAC prices for BREO ELLIPTA 200-25 MCG INHALR?

Since Oct 21, 2015, the NADAC for BREO ELLIPTA 200-25 MCG INHALR has ranged from a low of $4.5064 (Oct 21, 2015) to a high of $6.5159 (Aug 14, 2024), with a median of $5.9560 per EA.

Are there cheaper alternatives to BREO ELLIPTA 200-25 MCG INHALR?

Yes. 1 NADAC-published product shares the same active ingredient, strength, and dosage form. The lowest-priced option, BREO ELLIPTA 200-25 MCG INHALR, is $5.3639 per EA — about 18% below BREO ELLIPTA 200-25 MCG INHALR.

Who manufactures BREO ELLIPTA 200-25 MCG INHALR?

BREO ELLIPTA 200-25 MCG INHALR (NDC 00173088210) is labeled by GlaxoSmithKline LLC, and CMS classifies it as a brand product.